GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aroa Biosurgery ARX.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.51

-4.72%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Aroa Biosurgery

Its shares trade on ASX under the ticker ARX.AX. It has been listed since 24 July 2020. In the fiscal year to 31 March 2026, it reported revenue of NZD 114.9m and net income of NZD 5.2m. At that date it held total assets of NZD 100.5m and shareholders' equity of NZD 82.7m.

Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The company develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement and complex wounds. Its subsidiaries are Aroa Biosurgery Incorporated and Mesynthes Nominee Limited.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
24 Jul 2020
Employees
261
Website
aroa.com ↗

Leadership

Pay as last reported

  • Mr. James McLeanIndependent Non-Executive Chairman of the BoardNZD 144,035
  • Mr. Brian WardChief Executive Officer, Founder, Managing Director, Executive DirectorNZD 1.1m
  • Mr. James AgnewChief Financial Officer, Joint Company Secretary, since 2020NZD 627,006
  • Dr. Barnaby MayChief Scientific Officer, since 2022
  • Mr. Brad AdamsVice President - Commercial, USA
  • Mr. Rod StanleyVice President - Manufacturing
  • Ms. Tracy WeimarJoint Company Secretary
  • Mr. Philip McCawNon-Executive DirectorNZD 109,123
  • Dr. Catherine MohrNon-Executive Director
  • Mr. John DiddamsIndependent Non-Executive DirectorNZD 80,982
  • Ms. Darla HuttonIndependent Non-Executive Director
  • Mr. John PinionIndependent Non-Executive DirectorNZD 125,010

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Aroa Biosurgery Ltd. develops innovative wound care products using AROA ECM technology platform.
  • Endoform and Myriad Matrix support all phases of wound healing and complex tissue repair.
  • The company's subsidiaries include Aroa Biosurgery Incorporated and Mesynthes Nominee Limited.

Weaknesses

  • Aroa Biosurgery Ltd. has only 261 employees, which may limit scalability.
  • The company is listed on the NZX market with a 2020 listing date, indicating limited market presence.
  • Aroa Biosurgery Ltd. operates from Auckland, New Zealand, which may restrict global reach.

Opportunities

  • The global wound care market is expanding, offering growth potential for Aroa Biosurgery Ltd.
  • Aroa Biosurgery Ltd. can leverage AROA ECM technology for new product development.
  • The company's focus on soft tissue regeneration aligns with increasing healthcare demands.

Threats

  • Competition in the biotechnology sector may challenge Aroa Biosurgery Ltd.'s market position.
  • Regulatory changes in the Health Care industry could impact product approvals.
  • Economic downturns might reduce healthcare spending on advanced wound care products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.